Patents Assigned to Horizon Therapeutics, LLC
-
Patent number: 11014870Abstract: Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.Type: GrantFiled: May 7, 2019Date of Patent: May 25, 2021Assignee: Horizon Therapeutics, LLCInventors: Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
-
Patent number: 10668040Abstract: Nitrogen scavenging drugs such as glycerol phenylbutyrate can be administered safely to infants and toddlers with urea cycle disorders by adjusting the dosage based on one or more biomarkers selected from the group consisting of urinary-PAGN and plasma PAA:PAGN ratio.Type: GrantFiled: September 11, 2018Date of Patent: June 2, 2020Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 10617665Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: November 16, 2018Date of Patent: April 14, 2020Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 10329236Abstract: Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.Type: GrantFiled: September 6, 2017Date of Patent: June 25, 2019Assignee: Horizon Therapeutics, LLCInventors: Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
-
Patent number: 10183005Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: April 3, 2018Date of Patent: January 22, 2019Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 10183006Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: May 15, 2018Date of Patent: January 22, 2019Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 10183003Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: April 3, 2018Date of Patent: January 22, 2019Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 10183004Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: April 3, 2018Date of Patent: January 22, 2019Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 10183002Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: April 3, 2018Date of Patent: January 22, 2019Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 10045958Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: April 3, 2018Date of Patent: August 14, 2018Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 10045959Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: April 3, 2018Date of Patent: August 14, 2018Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 9999608Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: March 13, 2017Date of Patent: June 19, 2018Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 9962358Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: August 25, 2017Date of Patent: May 8, 2018Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 9962359Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.Type: GrantFiled: August 25, 2017Date of Patent: May 8, 2018Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
-
Patent number: 9914692Abstract: Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.Type: GrantFiled: May 25, 2016Date of Patent: March 13, 2018Assignee: Horizon Therapeutics, LLCInventors: Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
-
Patent number: 9561197Abstract: The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.Type: GrantFiled: September 11, 2012Date of Patent: February 7, 2017Assignee: Horizon Therapeutics, LLCInventors: Bruce Scharschmidt, Masoud Mokhtarani
